Literature DB >> 8866409

Risk factors for vascular disease and arteriovenous fistula dysfunction in hemodialysis patients.

S De Marchi1, E Falleti, R Giacomello, G Stel, E Cecchin, G Sepiacci, N Bortolotti, F Zanello, F Gonano, E Bartoli.   

Abstract

Vascular access dysfunction is an important cause of morbidity for dialysis patients and a major contributor to hemodialysis cost. Thrombosis is a leading cause of vascular access failure, and usually results from stenotic lesions in the venous outflow system. This study was designed to explore the impact of serum levels of various risk factors for thrombosis and accelerated fibrointimal hyperplasia on progressive stenosis, and the subsequent thrombosis of hemodialysis fistula. A cross-sectional and 2-yr prospective pilot study was performed in 30 nondiabetic hemodialysis patients with primary arteriovenous fistula. Venous dialysis pressure, urea recirculation, color Doppler sonography, and angiography were used to monitor vascular access patency. Eleven patients (37%) developed a progressive stenosis in the venous circuit, which was complicated by thrombosis in three patients. Compared with the patients without fistula dysfunction, these patients had higher serum levels of monocyte chemoattractant protein-1 and interleukin-6, two cytokines that regulate the proliferation of vascular smooth muscle cells, which is the key mechanism in the pathogenesis of fistula stenosis. In addition, they had hyperinsulinemia, hyperlipidemia, and increased plasma levels of two hemostasis-derived risk factors for thrombosis: plasminogen activator inhibitor type 1 and factor VII. Monocyte chemoattractant protein-1, interleukin-6, plasminogen activator inhibitor type 1, factor VII, triglycerides, and the ratios for cholesterol/HDL-cholesterol, apolipoprotein (apo) A-I/ apo C-III, apo A-I/apo B, and glucose/insulin were independent predictors of fistula dysfunction. This study demonstrates the influece of cytokines, hemostasis-derived vascular risk factor, hyperinsullnemia, and abnormallties of lipids and apolipoproteins on primary fistula survival. The assessment of these factors might be useful for the identification of the patients at risk of fistula stenosis and thrombosis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8866409     DOI: 10.1681/ASN.V781169

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  29 in total

Review 1.  Future research directions to improve fistula maturation and reduce access failure.

Authors:  Haidi Hu; Sandeep Patel; Jesse J Hanisch; Jeans M Santana; Takuya Hashimoto; Hualong Bai; Tambudzai Kudze; Trenton R Foster; Jianming Guo; Bogdan Yatsula; Janice Tsui; Alan Dardik
Journal:  Semin Vasc Surg       Date:  2016-08-26       Impact factor: 1.000

Review 2.  "Venopathy" at work: recasting neointimal hyperplasia in a new light.

Authors:  Alexander S Yevzlin; Micah R Chan; Yolanda T Becker; Prabir Roy-Chaudhury; Timmy Lee; Bryan N Becker
Journal:  Transl Res       Date:  2010-08-13       Impact factor: 7.012

3.  Adipose phenotype predicts early human autogenous arteriovenous hemodialysis remodeling.

Authors:  Christine R Mauro; Kui Ding; Hui Xue; Ming Tao; Alban Longchamp; Michael Belkin; Bruce S Kristal; C Keith Ozaki
Journal:  J Vasc Surg       Date:  2014-09-26       Impact factor: 4.268

4.  Characterization of a model of an arteriovenous fistula in the rat: the effect of L-NAME.

Authors:  Anthony J Croatt; Joseph P Grande; Melissa C Hernandez; Allan W Ackerman; Zvonimir S Katusic; Karl A Nath
Journal:  Am J Pathol       Date:  2010-04-02       Impact factor: 4.307

5.  Evaluation of the value of rapid D-dimer test in conjunction with cardiac troponin I test for early risk stratification of myocardial infarction.

Authors:  Shy-Shin Chang; Si-Huei Lee; Jiunn-Yih Wu; Hsiao-Chen Ning; Te-Fa Chiu; Feng-Lin Wang; Jung Hsiang Chen; Chih-Huang Li; Chien-Chang Lee; Rai-Chi Chan
Journal:  J Thromb Thrombolysis       Date:  2010-11       Impact factor: 2.300

6.  Anti-PF4/heparin antibodies are associated with arteriovenous fistula thrombosis in non-diabetic hemodialysis patients.

Authors:  Yueh-Feng Tsai; Chien-An Chen; Chieh Kuo; Kao-Chang Lin
Journal:  Clin Exp Nephrol       Date:  2011-11-01       Impact factor: 2.801

7.  Monocyte Chemoattractant Protein-1 Levels and Postangioplasty Restenosis of Arteriovenous Fistulas.

Authors:  Chih-Cheng Wu; Tsung-Yan Chen; Mu-Yang Hsieh; Lin Lin; Chung-Wei Yang; Shao-Yuan Chuang; Der-Cheng Tarng
Journal:  Clin J Am Soc Nephrol       Date:  2016-10-26       Impact factor: 8.237

8.  MCP-1 contributes to arteriovenous fistula failure.

Authors:  Julio P Juncos; Joseph P Grande; Lu Kang; Allan W Ackerman; Anthony J Croatt; Zvonimir S Katusic; Karl A Nath
Journal:  J Am Soc Nephrol       Date:  2010-11-29       Impact factor: 10.121

Review 9.  Vein graft adaptation and fistula maturation in the arterial environment.

Authors:  Daniel Y Lu; Elizabeth Y Chen; Daniel J Wong; Kota Yamamoto; Clinton D Protack; Willis T Williams; Roland Assi; Michael R Hall; Nirvana Sadaghianloo; Alan Dardik
Journal:  J Surg Res       Date:  2014-01-30       Impact factor: 2.192

10.  Increased venous proinflammatory gene expression and intimal hyperplasia in an aorto-caval fistula model in the rat.

Authors:  Karl A Nath; Sharan K R Kanakiriya; Joseph P Grande; Anthony J Croatt; Zvonimir S Katusic
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.